144 related articles for article (PubMed ID: 31744817)
1. A Versatile ES Cell-Based Melanoma Mouse Modeling Platform.
Bok I; Vera O; Xu X; Jasani N; Nakamura K; Reff J; Nenci A; Gonzalez JG; Karreth FA
Cancer Res; 2020 Feb; 80(4):912-921. PubMed ID: 31744817
[TBL] [Abstract][Full Text] [Related]
2. Build-a-Mouse: Melanoma Modeling Picks up Speed.
Thorkelsson A; Merlino G; Michael H
Cancer Res; 2020 Feb; 80(4):655-656. PubMed ID: 32060226
[TBL] [Abstract][Full Text] [Related]
3. Using the GEMM-ESC strategy to study gene function in mouse models.
Huijbers IJ; Del Bravo J; Bin Ali R; Pritchard C; Braumuller TM; van Miltenburg MH; Henneman L; Michalak EM; Berns A; Jonkers J
Nat Protoc; 2015 Nov; 10(11):1755-85. PubMed ID: 26492136
[TBL] [Abstract][Full Text] [Related]
4. Deciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma Progression.
Bonet C; Luciani F; Ottavi JF; Leclerc J; Jouenne FM; Boncompagni M; Bille K; Hofman V; Bossis G; Marco de Donatis G; Strub T; Cheli Y; Ohanna M; Luciano F; Marchetti S; Rocchi S; Birling MC; Avril MF; Poulalhon N; Luc T; Hofman P; Lacour JP; Davidson I; Bressac-de Paillerets B; Ballotti R; Marine JC; Bertolotto C
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376192
[TBL] [Abstract][Full Text] [Related]
5. Sirt5 is dispensable for Braf
Moon H; Zhu J; White AC
Exp Dermatol; 2019 Jan; 28(1):83-85. PubMed ID: 30471144
[TBL] [Abstract][Full Text] [Related]
6. A Series of BRAF- and NRAS-Driven Murine Melanoma Cell Lines with Inducible Gene Modulation Capabilities.
Bok I; Angarita A; Douglass SM; Weeraratna AT; Karreth FA
JID Innov; 2022 Mar; 2(2):100076. PubMed ID: 35146482
[TBL] [Abstract][Full Text] [Related]
7. CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma.
McNeal AS; Liu K; Nakhate V; Natale CA; Duperret EK; Capell BC; Dentchev T; Berger SL; Herlyn M; Seykora JT; Ridky TW
Cancer Discov; 2015 Oct; 5(10):1072-85. PubMed ID: 26183406
[TBL] [Abstract][Full Text] [Related]
8. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P
Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954
[TBL] [Abstract][Full Text] [Related]
9. Dermal Delivery of Constructs Encoding Cre Recombinase to Induce Skin Tumors in Pten
Deken MA; Song JY; Gadiot J; Bins AD; Kroon P; Verbrugge I; Blank CU
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999416
[TBL] [Abstract][Full Text] [Related]
10. BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.
Kakavand H; Walker E; Lum T; Wilmott JS; Selinger CI; Smith E; Saw RP; Yu B; Cooper WA; Long GV; O'Toole SA; Scolyer RA
Histopathology; 2016 Oct; 69(4):680-6. PubMed ID: 27151331
[TBL] [Abstract][Full Text] [Related]
11. Prenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cells.
Garay T; Kenessey I; Molnár E; Juhász É; Réti A; László V; Rózsás A; Dobos J; Döme B; Berger W; Klepetko W; Tóvári J; Tímár J; Hegedűs B
PLoS One; 2015; 10(2):e0117021. PubMed ID: 25646931
[TBL] [Abstract][Full Text] [Related]
12. Rapid validation of cancer genes in chimeras derived from established genetically engineered mouse models.
Huijbers IJ; Krimpenfort P; Berns A; Jonkers J
Bioessays; 2011 Sep; 33(9):701-10. PubMed ID: 21735458
[TBL] [Abstract][Full Text] [Related]
13. Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma.
Kumar R; Njauw CN; Reddy BY; Ji Z; Rajadurai A; Klebanov N; Tsao H
Oncogene; 2019 May; 38(18):3504-3520. PubMed ID: 30651601
[TBL] [Abstract][Full Text] [Related]
14. KIT Suppresses BRAF
Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ
Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418
[TBL] [Abstract][Full Text] [Related]
15. Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma.
Yang H; Kircher DA; Kim KH; Grossmann AH; VanBrocklin MW; Holmen SL; Robinson JP
Oncogene; 2017 Jul; 36(27):3842-3851. PubMed ID: 28263969
[TBL] [Abstract][Full Text] [Related]
16. [ Spectrum of oncogene mutations is different in melanoma subtypes].
Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
[TBL] [Abstract][Full Text] [Related]
17. Sox2 is not required for melanomagenesis, melanoma growth and melanoma metastasis in vivo.
Cesarini V; Guida E; Todaro F; Di Agostino S; Tassinari V; Nicolis S; Favaro R; Caporali S; Lacal PM; Botti E; Costanzo A; Rossi P; Jannini EA; Dolci S
Oncogene; 2017 Aug; 36(31):4508-4515. PubMed ID: 28368402
[TBL] [Abstract][Full Text] [Related]
18.
Hill KS; Roberts ER; Wang X; Marin E; Park TD; Son S; Ren Y; Fang B; Yoder S; Kim S; Wan L; Sarnaik AA; Koomen JM; Messina JL; Teer JK; Kim Y; Wu J; Chalfant CE; Kim M
Mol Cancer Res; 2019 Feb; 17(2):583-593. PubMed ID: 30355677
[TBL] [Abstract][Full Text] [Related]
19. A multidimensional impedance platform for the real-time analysis of single and combination drug pharmacology in patient-derived viable melanoma models.
Seidel D; Rothe R; Kirsten M; Jahnke HG; Dumann K; Ziemer M; Simon JC; Robitzki AA
Biosens Bioelectron; 2019 Jan; 123():185-194. PubMed ID: 30201332
[TBL] [Abstract][Full Text] [Related]
20. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.
Goel VK; Lazar AJ; Warneke CL; Redston MS; Haluska FG
J Invest Dermatol; 2006 Jan; 126(1):154-60. PubMed ID: 16417231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
